Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Vitiligo
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Vitiligo

Vitiligo: Is an acquired autoimmune disorder of pigmentation of the skin and mucous membranes where progressive dysfunction and destruction of melanocytes results in loss of skin pigmentation. Incidence: 1% of world population, 50% appearing before the age of 20 years. A family history may be present in up to 30% of cases. Associated with other autoimmune conditions, particularly thyroid disease occurring in 20% of patients over the age of 20 years. Also associated with Type 1 diabetes, pernicious anaemia, alopecia areata, Addison’s disease, systemic lupus erythematosus, rheumatoid arthritis and psoriasis. There is currently no definitive treatment, but spontaneous improvement may occur. Irrespective of clinical severity Vitiligo may cause significant psycho-social distress and referral for psychological support should always be considered. 

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

 

Treatment/ therapy

Severity 

Depends on proportions of physical appearance and psychological impact. 

Mild:  Localised segmental Vitiligo. Non segmental Vitiligo sparing face and hands. Minimal psychological impact. 

  • In absence of definitive treatment, for minimal disease with low psychological impact patients may not seek further treatment. 
  • Recommend a high-factor (SPF50+) sunscreen with protection against ultraviolet A and B. 
  • Check TSH and thyroid antibodies. 
  • For adults with limited areas on trunk and limbs a potent topical steroid may be applied once daily (off licence) for up to 2 months 
  • Not suitable for face and flexures. 
  • Topical calcineurin inhibitor may be useful such as Tacrolimus 0.1% applied BD for face and flexures 
  • Avoid use of sunbeds. 
  • Provide contact details for Changing Faces for advice on skin camouflage and the Vitiligo Society for further information and support.

Moderate: More widespread.  Acrofacial.  Significant psychological impact. 

  • Check TSH and thyroid antibodies. 
  • For adults with limited areas on trunk and limbs a potent topical steroid may be applied once daily (off licence) for up to 2 months or daily for one week on one week off for longer periods of time. Not suitable for face and flexures. 
  • Topical calcineurin inhibitor may be useful such as Tacrolimus 0.1% applied BD for face or flexures. Consider referral to secondary care if failing to respond to simple measures for further assessment  

Expert recommendations: camouflage 

  • Self-tanning agents in gel, cream, lotion or spray: These give the skin a brown colour that resembles a natural tan and normally lasts from 3 to 5 days. 
  • Highly pigmented cover creams: May require guidance on selection and application 

Severe:  Generalised / Universal / Active Progressive spread, Rapidly progressive spread and/or Major psychological impact 

For all patients for whom the condition is progressing rapidly; or where there is diagnostic uncertainty; or if the condition has a significant psychosocial impact; or the condition is not responding to topical treatment 

Refer to secondary care services for consideration of treatment with: 

  • Topical steroids 
  • Topical calcineurin inhibitor 
  • Narrowband – UVB 
  • Emerging treatments

NB. treatments may help but none are curative at present.

 

 

Referral Management

Severity 

Depends on proportions of physical appearance and psychological impact. 

Mild: Localised segmental Vitiligo. Non segmental Vitiligo sparing face and hands. Minimal psychological impact. 

Refer to secondary care: 

  • If the condition is progressing rapidly 
  • there is diagnostic uncertainty 
  • the condition has a significant psychosocial impact, or 
  • the condition is not responding to topical treatment. 

Moderate: More widespread.  Acrofacial.  Significant psychological impact. 

Refer to secondary care: 

  • If the condition is progressing rapidly 
  • there is diagnostic uncertainty 
  • the condition has a significant psychosocial impact, or 
  • the condition is not responding to topical treatment. 

Severe:  Generalised / Universal / Active Progressive spread, Rapidly progressive spread and/or Major psychological impact 

Refer to secondary care: 

  • If the condition is progressing rapidly 
  • there is diagnostic uncertainty 
  • the condition has a significant psychosocial impact, or 
  • the condition is not responding to topical treatment. 

Clinical resources

NICE CKS – Vitiligo   

BAD Guidelines – Vitiligo (2021)

European Dermatology Forum vitiligo guidelines 2012 

PCDS- Vitiligo

DermNet NZ- Vitiligo 

Clinical tips

  • Be aware of possible association with other autoimmune disorders. 
  • Post-inflammatory hypopigmentation can be common in skin of colour and should be clinically distinguishable from depigmentation seen in vitiligo, which may often be symmetrical. 
  • Psychological effects are important. Vitiligo is often immediately visible to others and those with the condition may suffer social and emotional consequences including low self-esteem, social anxiety, depression, stigmatization and, in extreme cases, rejection by those around them. This can be accentuated in darker skin types, where loss of pigment is more visible. 

Patient information resources

BAD patient information leaflet – Vitiligo:  

BAD patient information leaflet – Skin camouflage:   

Patient.info leaflet – Vitiligo:   

NHS Conditions- Vitiligo:  

ICD search categories

Epidermal/ 

Appendageal 

ICD11 code - ED63.0 

Editorial Information

Last reviewed: 30/05/2023

Next review date: 30/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society